CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study
Inclusion criteria: Refractory neuroblastoma with original diagnosis based on tumor
histopathology or elevated urine VMA with typical tumor cells in the bone marrow.
Type of Study:
Primary Purpose: Treatment
United States: Federal Government
- Relapsed and refractory neuroblastoma
|Children's Hospital of Philadelphia||Philadelphia, Pennsylvania 19104|